Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 38
Filter
1.
RMD Open ; 5(2): e000887, 2019.
Article in English | MEDLINE | ID: mdl-31452928

ABSTRACT

Objective: In MOBILITY (NCT01061736), sarilumab significantly reduced disease activity, improved physical function and inhibited radiographic progression at week 52 versus placebo in patients with rheumatoid arthritis (RA) and an inadequate response to methotrexate. We report 5-year safety, efficacy and radiographic outcomes of sarilumab from NCT01061736 and the open-label extension (EXTEND; NCT01146652), in which patients received sarilumab 200 mg every 2 weeks (q2w) + methotrexate. Methods: Patients (n=1197) with moderately to severely active RA were initially randomised to placebo, sarilumab 150 mg or sarilumab 200 mg subcutaneously q2w plus weekly methotrexate for 52 weeks. Completers were eligible to enrol in the open-label extension and receive sarilumab 200 mg q2w + methotrexate. Results: Overall, 901 patients entered the open-label extension. The safety profile remained stable over 5-year follow-up and consistent with interleukin-6 receptor blockade. Absolute neutrophil count <1000 cells/mm3 was observed but not associated with increased infection rate. Initial treatment with sarilumab 200 mg + methotrexate was associated with reduced radiographic progression over 5 years versus sarilumab 150 mg + methotrexate or placebo + methotrexate (mean±SE change from baseline in van der Heijde-modified Total Sharp Score: 1.46±0.27, 2.35±0.28 and 3.68±0.27, respectively (p<0.001 for each sarilumab dose versus placebo)). Clinical efficacy was sustained through 5 years according to Disease Activity Score (28-joint count) using C reactive protein, Clinical Disease Activity Index (CDAI) and Health Assessment Questionnaire-Disability Index. The number of patients achieving CDAI ≤2.8 at 5 years was similar among initial randomisation groups (placebo, 76/398 (19%); sarilumab 150 mg, 68/400 (17%); sarilumab 200 mg, 84/399 (21%)). Conclusion: Clinical efficacy, including inhibition of radiographic progression, reduction in disease activity and improvement in physical function, was sustained with sarilumab + methotrexate over 5 years. Safety appeared stable over the 5-year period.


Subject(s)
Antibodies, Monoclonal, Humanized/therapeutic use , Antirheumatic Agents/therapeutic use , Arthritis, Rheumatoid/drug therapy , Methotrexate/therapeutic use , Adult , Antibodies, Monoclonal, Humanized/administration & dosage , Antibodies, Monoclonal, Humanized/adverse effects , Antirheumatic Agents/administration & dosage , Antirheumatic Agents/adverse effects , Arthritis, Rheumatoid/diagnostic imaging , Arthritis, Rheumatoid/physiopathology , C-Reactive Protein/drug effects , Disease Progression , Drug Therapy, Combination , Exercise , Female , Humans , Injections, Subcutaneous/methods , Male , Methotrexate/administration & dosage , Methotrexate/adverse effects , Middle Aged , Neutrophils/drug effects , Patient Safety , Placebos/administration & dosage , Radiography/statistics & numerical data , Radiography/trends , Receptors, Interleukin-6/antagonists & inhibitors , Treatment Outcome
2.
Endokrynol Pol ; 67(4): 350-8, 2016.
Article in English | MEDLINE | ID: mdl-27387240

ABSTRACT

INTRODUCTION: After thyroidectomy and radioiodine therapy, patients with differentiated thyroid cancer (DTC) are indefinitely treated with levothyroxine (L-T4). Osteoporosis is a debated consequence of hypothyroxinaemia. The aim of this study was to evaluate bone mineral density (BMD) and fracture risk assessed by FRAX in a cohort of DTC women. MATERIAL AND METHODS: Seventy-four women with DTC (aged 56.5 ± 9.9 years) treated at the mean age of 51.9 ± 12.0 years were studied. Baseline BMD and FRAX were evaluated after 3.0 years (median). BMD and FRAX were further evaluated 5.5 years (median) after the baseline evaluation. A cohort of 120 euthyroid women, matched for age, BMI, and menopausal status, were evaluated as controls. RESULTS: L-T4 dosages were 813.6 ± 208.8 µg/week and 782.1 ± 184.4 µg/week at the baseline and second evaluation, respectively. The risks of major osteoporotic fracture (MOF) and hip fracture (HF) were similar in DTC patients and in controls. In DTC women, significant changes in FRAX were found, with a higher increase in the probability of HF than of MOF. A similar change was found in controls. A significant inverse correlation (P < 0.001) between L-T4 dosage and HF/MOF probability on both first and second evaluations was found. A significant inverse correlation (P = 0.05) was found between fT4, TSH and duration of therapy and HF/MOF probability only on the second evaluation. CONCLUSIONS: FRAX increase is a multi-factorial, age-related phenomenon. The absence of correlations between L-T4 dosage, length of therapy or fT4 levels and FRAX does not enable us to attribute an increased fracture risk to DTC women with well-controlled disease on therapy. (Endokrynol Pol 2016; 67 (4): 350-358).


Subject(s)
Osteoporotic Fractures/etiology , Thyroid Neoplasms/surgery , Thyroxine/therapeutic use , Adult , Aged , Female , Humans , Iodine Radioisotopes/adverse effects , Iodine Radioisotopes/therapeutic use , Middle Aged , Osteoporotic Fractures/diagnosis , Osteoporotic Fractures/prevention & control , Postoperative Period , Risk , Thyroid Neoplasms/drug therapy , Thyroidectomy/adverse effects , Thyroxine/administration & dosage
3.
Clin Exp Rheumatol ; 34(3): 500-6, 2016.
Article in English | MEDLINE | ID: mdl-26940199

ABSTRACT

OBJECTIVES: To evaluate the anti-inflammatory effect of CTLA4-Ig (abatacept) and dexamethasone (DEX) monotreatment versus their combination and adding methotrexate (MTX) on cultured human macrophages. METHODS: THP-1 cells, activated into macrophages (PMA 0.05 µg/ml), were cultured for 3 and 24 hrs with CTLA4-Ig (500 µg/ml), DEX (10-8 M), MTX (0.05 µg/ml), and CTLA4-Ig combined with DEX or CTLA4-Ig combined with DEX plus MTX. CTLA4-Ig/CD86 interaction was evaluated by FACS analysis. Quantitative real time-PCR (qRT-PCR), immunocytochemistry (ICC) and immunoassay (ELISA) analysis for inflammatory cytokine (IL-1ß, TNF-α, IL-6) expression were performed. RESULTS: FACS analysis showed in macrophages treated with CTLA4-Ig alone, CTLA4-Ig-DEX and CTLA4-Ig-DEX-MTX a CD86 decrease of almost 35%, versus untreated cells (CNT). After 3 hrs, macrophages treated with DEX alone or with CTLA4-Ig-DEX or CTLA4-Ig-DEX-MTX showed a significant reduction (p<0.05) for all cytokines gene expression, that was still significant for IL-1ß after 24 hrs (p<0.05). After 3 hrs, CTLA4-Ig alone significantly (p<0.05) reduced all cytokine genes; however, after 24 hrs still evident only for TNF-α (p<0.05). After 24 hrs CTLA4-Ig-DEX induced a significant decrease of gene expression (p<0.05) for TNF-α and IL-6, whereas CTLA4-Ig-DEX-MTX induced a decrease (p<0.05) limited to IL-6, versus CNT. Finally, ICC showed, after 24 hrs of CTLA4-Ig-DEX or CTLA4-Ig-DEX-MTX treatment a reduction (p<0.05) of IL-1ß and IL-6 expression, versus CNT; DEX alone reduced only IL-1ß (p<0.05). ELISA analysis confirmed these results. CONCLUSIONS: CTLA4-Ig-DEX and CTLA4-Ig-DEX-MTX combined treatments, decreased at any level the inflammatory cytokine expression more efficiently then monotreatments on activated cultured human macrophages.


Subject(s)
Abatacept/pharmacology , Cytokines , Dexamethasone/pharmacology , Methotrexate/pharmacology , Cells, Cultured , Cytokines/genetics , Cytokines/metabolism , Drug Therapy, Combination , Gene Expression/drug effects , Gene Expression Profiling , Glucocorticoids/pharmacology , Humans , Immunosuppressive Agents/pharmacology , Macrophages/metabolism , Treatment Outcome
4.
J Rheumatol ; 43(3): 495-503, 2016 Mar.
Article in English | MEDLINE | ID: mdl-26834211

ABSTRACT

OBJECTIVE: To evaluate the efficacy and safety of secukinumab, a fully human antiinterleukin-17A monoclonal antibody, administered with an intravenous (IV) or subcutaneous (SC) loading regimen versus placebo, in patients with active rheumatoid arthritis (RA). METHODS: In this phase II, double-blind, double-dummy, 52-week study (ClinicalTrials.gov NCT01359943), 221 patients with inadequate response to methotrexate were randomized (2:2:1) to secukinumab, IV loading 10 mg/kg at baseline, Weeks 2 and 4, then SC 150 mg every 4 weeks (n = 88); secukinumab SC loading 150 mg once weekly for 5 weeks, then every 4 weeks (n = 89); or a matching placebo (followed by secukinumab 150 mg every 4 weeks starting Week 16; n = 44). The primary endpoint was superior efficacy of pooled secukinumab versus placebo using American College of Rheumatology 20% response (ACR20) at Week 12. RESULTS: The primary efficacy endpoint was not met: ACR20 response at Week 12 was 49.2% for pooled secukinumab versus 40.9% for placebo (p = 0.3559). These variables improved significantly with pooled secukinumab versus placebo at Week 12 (all p < 0.05): the 28-joint Disease Activity Score (DAS28), patient's and physician's global assessment of disease activity, patient's assessment of RA pain, and high-sensitivity C-reactive protein levels. Results of continuous efficacy outcomes were similar between the IV and SC loading regimens. The most frequent adverse events were infections, with similar rates across secukinumab and placebo. CONCLUSION: Although the primary endpoint (ACR20) was not met, secukinumab demonstrated improved efficacy in reducing disease activity over placebo as measured by DAS28 and other secondary endpoints.


Subject(s)
Antibodies, Monoclonal/therapeutic use , Antirheumatic Agents/therapeutic use , Arthritis, Rheumatoid/drug therapy , Administration, Intravenous , Adult , Aged , Antibodies, Monoclonal/administration & dosage , Antibodies, Monoclonal/adverse effects , Antibodies, Monoclonal, Humanized , Antirheumatic Agents/administration & dosage , Antirheumatic Agents/adverse effects , Double-Blind Method , Drug Administration Schedule , Female , Humans , Injections, Subcutaneous , Male , Middle Aged , Treatment Outcome
5.
Clin Exp Rheumatol ; 33(2): 250-4, 2015.
Article in English | MEDLINE | ID: mdl-25896473

ABSTRACT

OBJECTIVES: Previous studies have reported the presence of CD86 (B7.2) costimulatory molecule on endothelial cells (ECs) and recent data have shown that CTLA4-Ig (abatacept), used as a biological agent in rheumatoid arthritis, interacts with CD86 expressed on different cells involved in synovitis. Therefore, the effects of CTLA4-Ig/CD86 interaction on VEGFR-2 (vascular endothelial growth factor receptor 2) and ICAM1 expression, were evaluated in cultured ECs. METHODS: Activated ECs (γIFN 500 U/ml or IL-17 100 ng/ml), treated with CTLA4-Ig (10, 100, 500 µg/ml) were analysed for CD86, VEGFR-2 and ICAM1 expression, by flow cytometry (FACS), by western blot (WB) and quantitative real time PCR (qRT-PCR). RESULTS: Following CTLA4-Ig treatment (10, 100, 500 µg/ml; 24 hrs), activated ECs decreased their CD86-positivity at FACS: 66, 59, 51%, respectively, versus 68% of untreated cells (cnt) (for γIFN-activated cells) and 42, 47, 46% versus 71% (cnt) (for IL-17-activated ECs). Gamma-IFN-activated ECs, treated with CTLA4-Ig, showed a dose-dependent decrease only for ICAM1 fluorescence. Whereas, WB showed a significant decrease (p<0.05) for both ICAM1 and VEGFR-2 after CTLA4-Ig 500 µg/ml (3 and 24 hrs) and for VEGFR-2 also after CTLA4-Ig 100 µg/ml (3 hrs). QRT-PCR showed a significant decrease (p<0.05) for VEGFR-2 after CTLA4-Ig 500 µg/ml (3 and 24 hrs) and after CTLA4-Ig 100 µg/ml (limited at 3 hrs). QRT-PCR for ICAM1 was negative at 3 and 24 hrs, possibly since it was to late to be detected. CONCLUSIONS: Results support a CTLA4-Ig/CD86 interaction on γIFN and IL-17 activated ECs modulation, in the expression of VEGFR-2 and ICAM1, both relevant for inflammatory and angiogenetic processes, suggesting ECs as a further target for abatacept.


Subject(s)
B7-2 Antigen/drug effects , Endothelial Cells/drug effects , Immunoconjugates/pharmacology , Immunosuppressive Agents/pharmacology , Intercellular Adhesion Molecule-1/metabolism , Vascular Endothelial Growth Factor Receptor-2/metabolism , Abatacept , B7-2 Antigen/metabolism , Cells, Cultured , Dose-Response Relationship, Drug , Endothelial Cells/immunology , Endothelial Cells/metabolism , Humans , Intercellular Adhesion Molecule-1/genetics , Interferon-gamma/pharmacology , Interleukin-17/pharmacology , RNA, Messenger/metabolism , Vascular Endothelial Growth Factor Receptor-2/genetics
6.
Ann N Y Acad Sci ; 1317: 39-46, 2014 May.
Article in English | MEDLINE | ID: mdl-24739090

ABSTRACT

The endogenous serum metabolite of vitamin D (calcitriol, 1,25(OH)2 D3 ) is considered a true steroid hormone (D hormone), and like glucocorticoids (GCs) and gonadal hormones, may exert several immunomodulatory activities. Serum vitamin D deficiency (25(OH) D), and therefore reduced 1,25(OH)2 D3 availability, is considered a risk factor for several chronic/inflammatory or autoimmune conditions, including infectious diseases, type 1 diabetes, multiple sclerosis, and especially autoimmune rheumatic diseases (ARD). In ARD in particular, 1,25(OH)2 D3 regulates both innate and adaptive immunity, potentiating the innate response (antimicrobial activity) but reducing adaptive immunity (antigen presentation, T and B cell activities). Regarding a possible synergism between vitamin D and GCs, several studies show that 1,25(OH)2 D3 has significant additive effects on dexamethasone-mediated inhibition of human lymphocyte and monocyte proliferation. Conversely, vitamin D deficiency seems to play a role in increasing autoantibody production by B cells, and seasonal vitamin D declines may trigger flares in ARD, as recently shown. Finally, 1,25(OH)2 D3 seems to reduce aromatase activity and limit the negative effects related to increased peripheral estrogen metabolism (cell proliferation, B cell overactivity).


Subject(s)
Arthritis, Rheumatoid/immunology , Calcitriol/physiology , Glucocorticoids/physiology , Gonadal Hormones/physiology , Autoimmunity , Humans , Immunologic Factors/physiology , Risk , Sunlight , Vitamin D/physiology , Vitamin D Deficiency/immunology
7.
J Rheumatol ; 41(5): 881-6, 2014 May.
Article in English | MEDLINE | ID: mdl-24692525

ABSTRACT

OBJECTIVE: To evaluate the longterm effects of endothelin-1 (ET-1) antagonism on peripheral blood perfusion (PBP) in patients with systemic sclerosis (SSc). METHODS: Twenty-six patients with SSc already receiving cyclic intravenous iloprost (ILO) for severe Raynaud phenomenon were enrolled. Thirteen patients continued the treatment for a further 3 years (ILO group) and 13 patients, because of the appearance of digital ulcers, received in addition bosentan (BOS; 125 mg twice/day) for 3 years (ILO + BOS group). Both PBP at fingertips and nailfold microangiopathy were evaluated yearly by laser Doppler flowmetry and nailfold videocapillaroscopy, respectively. RESULTS: A progressive significant increase of PBP was observed in the ILO + BOS group during the 3 followup years (p = 0.0007, p = 0.0002, p = 0.01, respectively). In contrast, an insignificant progressive decrease of PBP was observed in the ILO group. Difference of perfusion between the PBP evaluations at basal temperature and at 36 °C (to test capillary dilation capacity), was found progressively decreased during the 3-year followup only in the ILO group (p = 0.05, p = 0.26, p = 0.09, respectively). A progressive increase of nailfold capillary number was observed only in the ILO + BOS group after 2 and 3 years of followup (p = 0.05). CONCLUSION: Longterm treatment of SSc patients with ET-1 antagonism, in combination with ILO, seems to increase fingertip blood perfusion, as well as both capillary dilation capacity and number.


Subject(s)
Endothelin Receptor Antagonists/therapeutic use , Fingers/blood supply , Iloprost/therapeutic use , Regional Blood Flow/drug effects , Scleroderma, Systemic/drug therapy , Sulfonamides/therapeutic use , Aged , Bosentan , Female , Humans , Laser-Doppler Flowmetry , Male , Microscopic Angioscopy , Middle Aged , Prospective Studies , Time Factors , Treatment Outcome , Vasodilator Agents/therapeutic use
8.
Clin Exp Rheumatol ; 31(6): 943-6, 2013.
Article in English | MEDLINE | ID: mdl-24295474

ABSTRACT

OBJECTIVES: The transcription factor NF-kB is involved in the expression of several genes linked to the immune response, including those of pro-inflammatory cytokines. We investigated cytokine production and NF-kB expression following CTLA4-Ig (abatacept) treatment of cultured human macrophages. METHODS: Human THP1 cells, differentiated in macrophages, were treated with CTLA4-Ig (100, 500 µg/ml; 3,12,24 hours). Quantitative RT-PCR analysis (qRT-PCR) of mRNA for NF-kB, IKBα and for IL-6, TNF-α, IL-1ß, was performed after 3 and 12 hours from treatment. Western blot (WB) analysis for NF-kB and IKBα was performed after 24 hours from treatment. RESULTS: NF-kB gene expression was significantly downregulated (p<0.05), at 3 and 12 hours from CTLA4-Ig treatment, vs. untreated cells (cnt). IKBα resulted significantly increased vs. cnt (p<0.05), at 12 hours from CTLA4-Ig [500 µg/ml] treatment. After 3 hours, CTLA4-Ig [100 µg/ml] induced a significant decrease of TNF-α and IL-6 (p<0.05), vs. cnt and CTLA4-Ig [500 µg/ml] further reduced TNF-α (p<0.001), vs. cnt. After 12 hours from CTLA4-Ig treatment, a significant downregulation for IL-6 and IL1ß expression (p<0.001), vs. cnt, was still evident. Results were confirmed by WB. CONCLUSIONS: NF-kB pathway seems to be implicated in the CTLA4-Ig modulation of macrophage cytokine expression. NF-kB expression resulted downregulated while its cytoplasmatic inhibitor IKBα was increased.


Subject(s)
I-kappa B Proteins/metabolism , Immunoconjugates/pharmacology , Macrophages/drug effects , NF-kappa B/metabolism , Abatacept , Blotting, Western , Cell Line, Tumor , Down-Regulation , Flow Cytometry , Humans , I-kappa B Proteins/genetics , Interleukin-1beta/metabolism , Interleukin-6/metabolism , Macrophages/immunology , NF-KappaB Inhibitor alpha , NF-kappa B/genetics , RNA, Messenger/metabolism , Real-Time Polymerase Chain Reaction , Reverse Transcriptase Polymerase Chain Reaction , Signal Transduction/drug effects , Time Factors , Tumor Necrosis Factor-alpha/metabolism , Up-Regulation
9.
Clin Exp Rheumatol ; 29(3 Suppl 66): S7-14, 2011.
Article in English | MEDLINE | ID: mdl-21906423

ABSTRACT

Given the availability of novel biologic agents for the treatment of rheumatoid arthritis (RA), various national scientific societies have developed specific recommendations in order to assist rheumatologists in prescribing these drugs. The Italian Society for Rheumatology (Società Italiana di Reumatologia, SIR) decided to update its recommendations and, to this end, a systematic literature review was carried out and the evidence derived from it was discussed and summarised as expert opinions. Levels of evidence, strength of recommendations and levels of agreement were reported. The recommendations reported are intended to help prescribing rheumatologists to optimise the use of biologic agents in patients with RA seen in everyday practice; they are not to be considered as a regulatory rule.


Subject(s)
Antirheumatic Agents/therapeutic use , Arthritis, Rheumatoid/therapy , Biological Products/therapeutic use , Biological Therapy/standards , Rheumatology/standards , Societies, Medical/standards , Evidence-Based Medicine/standards , Humans , Italy , Patient Selection , Treatment Outcome
10.
Clin Rheumatol ; 30(11): 1433-46, 2011 Nov.
Article in English | MEDLINE | ID: mdl-21607551

ABSTRACT

The aim of this 13-week, multicenter, randomized, double-blind, double-dummy, placebo- and positive-internal (celecoxib)-controlled, parallel-group study was to demonstrate the efficacy, safety, and tolerability of lumiracoxib in primary hip osteoarthritis (OA) patients. Eligible patients (n = 1,262; ACR criteria) were randomized (1:1:1) to receive lumiracoxib 100 mg once daily (o.d.) (n = 427), celecoxib 200 mg o.d. (n = 419), or matching placebo o.d. (n = 416) administered orally. The primary objective was to compare lumiracoxib 100 mg o.d. and placebo with respect to three co-primary efficacy variables: the pain subscale of the Western Ontario and McMaster Universities Osteoarthritis Index Likert version 3.1 (WOMAC™ LK 3.1) questionnaire, the function subscale of the WOMAC™ LK 3.1 questionnaire, and patient's global assessment of disease activity (100-mm visual analog scale (VAS)) after 13 weeks of treatment. Of the 1,262 randomized patients, 951 completed the study. All randomized patients were included in the intention-to-treat and safety populations. Lumiracoxib was superior to the placebo (p < 0.001) after 13 weeks for all three co-primary endpoints. By week 13, the patient's global assessment of disease activity (100-mm VAS) improved by 23.3 mm (±SD, 27.83 mm) with lumiracoxib and 13.3 mm (±26.71 mm) with placebo. The WOMAC™ function score decreased by 10.4 (±13.56) with lumiracoxib and 6.8 (±12.55) with placebo. The WOMAC™ pain scores decreased by 3.4 (±4.16) with lumiracoxib and 2.2 (±3.94) with placebo at week 13. Similar results were observed for secondary endpoints: OA pain intensity and WOMAC™ total score. Lumiracoxib was similar to celecoxib for all three co-primary endpoints. All treatments were well tolerated. In conclusion, lumiracoxib is effective in reducing pain and improving function in hip OA patients.


Subject(s)
Cyclooxygenase 2 Inhibitors/therapeutic use , Diclofenac/analogs & derivatives , Osteoarthritis, Hip/drug therapy , Adult , Aged , Aged, 80 and over , Cyclooxygenase 2 Inhibitors/adverse effects , Diclofenac/adverse effects , Diclofenac/therapeutic use , Double-Blind Method , Female , Humans , Male , Middle Aged , Pain/drug therapy , Pain Measurement , Treatment Outcome
12.
J Rheumatol ; 37(6): 1174-80, 2010 Jun.
Article in English | MEDLINE | ID: mdl-20436070

ABSTRACT

OBJECTIVE: To investigate possible correlations between fingertip blood perfusion (FBP) status, assessed by laser Doppler flowmetry (LDF), and morphological microvascular abnormalities, detected by nailfold videocapillaroscopy (NVC), in patients with systemic sclerosis (SSc). The effects on FBP of intravenous (IV) treatment with the prostacyclin analog iloprost were also investigated. METHODS: Thirty-four consecutive patients with SSc and 16 healthy subjects were evaluated. LDF was performed by analyzing blood perfusion at the fingertips in both hands. Patients with SSc were distributed into the appropriate NVC pattern of microangiopathy (early, active, and late). Iloprost was administered to inpatients with SSc by 24-hour IV infusion for 7 consecutive days (4 microg/h). RESULTS: FBP was significantly lower in patients with SSc (p < 0.05) compared to controls. Heating of the LDF probe at 36 degrees C induced a significant increase of FBP in all subjects (p < 0.001), but the slope of variation was significantly lower in patients with SSc compared to controls (p < 0.05). Patients with SSc showing the late NVC pattern of microangiopathy had significantly lower FBP than patients with the active and early NVC patterns (p < 0.05). A negative correlation was observed between FBP and NVC rating of the microvascular damage (p < 0.05). After iloprost treatment, a significant increase of FBP was observed in patients with SSc (p < 0.05). CONCLUSION: Patients with SSc show a decreased FBP partially reversible by local skin heating. The FBP correlated negatively with the extent of nailfold microvascular damage, and IV iloprost treatment increased the FBP.


Subject(s)
Laser-Doppler Flowmetry/methods , Nails/blood supply , Raynaud Disease/pathology , Scleroderma, Systemic/pathology , Capillaries/drug effects , Capillaries/pathology , Capillaries/physiology , Capillaries/physiopathology , Female , Humans , Hyperthermia, Induced , Iloprost/therapeutic use , Injections, Intravenous , Microcirculation/drug effects , Microcirculation/physiology , Microscopic Angioscopy , Middle Aged , Nails/drug effects , Raynaud Disease/complications , Raynaud Disease/drug therapy , Raynaud Disease/physiopathology , Scleroderma, Systemic/complications , Scleroderma, Systemic/drug therapy , Scleroderma, Systemic/physiopathology , Vasodilation/drug effects , Vasodilation/physiology , Vasodilator Agents/therapeutic use
13.
Ann N Y Acad Sci ; 1193: 15-21, 2010 Apr.
Article in English | MEDLINE | ID: mdl-20398002

ABSTRACT

The effects of low dose prednisone (PD) alone or in combination with leflunomide (LEF) were tested on inflammatory gene expression in early rheumatoid arthritis (RA). Ten RA patients were assigned as group A (untreated)and group B (pretreated with PD 5 mg/day for 3 months -T0). Therefore, both groups were treated with LFN (20mg/day). Expression ratio of 34 inflammatory genes was detected by microarray analysis in early RA patients and CNT (5), before (T0), and after 3 months (T1) of combined therapy (PN+LFN). At T0, 17 genes linked with arthritis were found altered in early RA, (A and B groups), compared to CNT. At T1 in the group A, 41% of genes were found unchanged, 12% upregulated, and 47% downregulated, whereas in the group B, 65% of genes were found unchanged, 6% upregulated, and 29% downregulated. The results suggest that the combination of PN and LEF seems to play a synergistic effect by modulating some inflammatory genes in early RA.


Subject(s)
Antirheumatic Agents/therapeutic use , Arthritis, Rheumatoid/drug therapy , Glucocorticoids/therapeutic use , Inflammation/genetics , Isoxazoles/therapeutic use , Prednisone/therapeutic use , Adult , Case-Control Studies , Cells, Cultured , Dose-Response Relationship, Drug , Drug Synergism , Drug Therapy, Combination , Female , Gene Expression Profiling , Gene Expression Regulation , Humans , Leflunomide , Leukocytes, Mononuclear/cytology , Leukocytes, Mononuclear/drug effects , Male , Microarray Analysis , Middle Aged , RNA, Messenger/isolation & purification , RNA, Messenger/metabolism , Time Factors , Treatment Outcome
14.
Ann N Y Acad Sci ; 1193: 25-9, 2010 Apr.
Article in English | MEDLINE | ID: mdl-20398004

ABSTRACT

To investigate the effects of 17beta-estradiol (E2) on extracellular matrix (ECM) protein synthesis (collagen type I, fibronectin, and laminin) using cultures of normal and scleroderma (SSc) skin fibroblasts. Primary fibroblasts cultures, obtained from skin biopsies of six female voluntary subjects and three female SSc patients, were treated for 24 h with E2 (10(-10)M) alone or in combination with tamoxifene (TAM, 10(-7)M) as an estrogen receptor (ER) antagonist. ECM protein synthesis was analyzed by immunocytochemistry and Western blotting. E2 induced a significant increase of fibronectin, collagen type I, and laminin synthesis both in normal (P < 0.01, P < 0.05, P < 0.01, respectively) and SSc fibroblasts (P < 0.001, P < 0.05, P < 0.001, respectively) when compared to untreated fibroblasts. TAM induced a significant decrease of ECM protein synthesis when compared to E2-treated TAM-untreated fibroblasts. This study seems to support important modulatory effects of E2 in the fibrotic progression of the SSc process via ER interactions.


Subject(s)
Estrogens/pharmacology , Extracellular Matrix/metabolism , Fibroblasts/metabolism , Scleroderma, Localized/metabolism , Skin/metabolism , Aged , Blotting, Western , Case-Control Studies , Cells, Cultured , Collagen Type I/metabolism , Drug Interactions , Estradiol/pharmacology , Extracellular Matrix/drug effects , Female , Fibronectins/metabolism , Humans , Immunohistochemistry , Laminin/metabolism , Middle Aged , Scleroderma, Localized/pathology , Tamoxifen/pharmacology , Time Factors
15.
Ann N Y Acad Sci ; 1193: 30-5, 2010 Apr.
Article in English | MEDLINE | ID: mdl-20398005

ABSTRACT

Rheumatoid arthritis (RA) prevalence is greater in females than in males, supporting estrogens as modulators of immune response. Leflunomide (LEF) is employed in the RA treatment. We studied the combinatory effects of LEF active metabolite A77 1726 (LEF-M) and 17beta-estradiol (E2) on inflammatory cytokine production by cultured macrophages obtained from activated human monocytes (THP-1 cells). Macrophages were cultured with LEF-M alone and in combination with E2. IL-6, TNF-alpha, and TGF-beta were evaluated by immunocytochemistry (ICC), Western blot (WB), and reverse transcriptase-polymerase chain reaction (RT-PCR). ICC, as well as WB and RT-PCR, showed that LEF-M, in respect to untreated cells, significantly downregulated the cytokine production (IL-6 P < 0.01, TNF-alphaP < 0.001, TGF-betaP < 0.01). On the contrary, E2 increased the cytokine production, a result that was significantly reversed when LEF-M was subsequently added (IL-6, TNF-alpha, TGF-betaP < 0.001 vs. E2). E2 seems to contrast the LEF-M activity. These results might support a more efficient therapeutical effect of LEF in male with respect to female RA patients.


Subject(s)
Anti-Inflammatory Agents, Non-Steroidal/pharmacology , Cytokines/biosynthesis , Estrogens/metabolism , Isoxazoles/pharmacology , Monocytes/drug effects , Aniline Compounds/metabolism , Blotting, Western , Cell Differentiation/drug effects , Cells, Cultured , Crotonates , Drug Interactions , Estradiol/metabolism , Estradiol/pharmacology , Estrogens/pharmacology , Humans , Hydroxybutyrates/metabolism , Immunohistochemistry , Interleukin-6/biosynthesis , Leflunomide , Macrophages/drug effects , Macrophages/immunology , Monocytes/immunology , Nitriles , Reverse Transcriptase Polymerase Chain Reaction , Tetradecanoylphorbol Acetate/pharmacology , Toluidines , Transforming Growth Factor beta/biosynthesis , Tumor Necrosis Factor-alpha/biosynthesis
16.
Arthritis Res Ther ; 11(6): R176, 2009.
Article in English | MEDLINE | ID: mdl-19930661

ABSTRACT

INTRODUCTION: Co-stimulatory signal B7(CD80/CD86):CD28 is needed in order to activate T cells in immune response. Cytotoxic T lymphocyte-associated antigen-4-immunoglobulin (CTLA4-Ig) binding to the B7 molecules on antigen-presenting cells downregulates this activation and represents a recent biological treatment in rheumatoid arthritis (RA). Objectives of the study were to investigate the presence of the B7.2 (CD86) molecule and its masking by CTLA4-Ig on cultures of both RA synovial macrophages (RA SM), and of macrophages differentiated from THP-1 cells (M). In addition, the anti-inflammatory effects of CTLA4-Ig on co-cultures of RA SM and M with activated T cells were tested. METHODS: All macrophages were co-cultured for 24 hours with activated T cells, without or with CTLA4-Ig (10, 100, 500 microg/ml for 1 hour, 3 hours and overnight, respectively). Immunofluorescence (IF) staining for B7.2, and an analysis of inflammatory cytokine expression (interleukin (IL) -6, tumor necrosis factor (TNF) alpha, IL-1beta, transforming growth factor (TGF) beta) by immunocytochemistry (ICC), western blot (WB) and reverse transcriptase-polymerase chain reaction (RT-PCR) were performed. RESULTS: Macrophages showed intense B7.2 expression. CTLA4-Ig/B7.2 masking was evident for all macrophages, even after only 1 hour of cell culture (range from 10 to 100 microg/ml). ICC of co-cultures showed a dose-dependent decrease in inflammatory cytokines (P < 0.001 for IL-6, TNFalpha, IL-1beta and TGFbeta). Data were confirmed by WB and RT-PCR analysis. CONCLUSIONS: Optimal concentrations of CTLA4-Ig for the CTLA4-Ig/B7.2 masking on activated macrophages were identified and were found to induce significant downregulation in the cell production of IL-6, TNFalpha, IL1-beta and TGFbeta. In conclusion, macrophages would appear to be a sensitive target for CTLA4-Ig treatment in RA.


Subject(s)
Antirheumatic Agents/pharmacology , Arthritis, Rheumatoid/immunology , Cytokines/drug effects , Immunoconjugates/pharmacology , Macrophages/drug effects , Abatacept , Arthritis, Rheumatoid/drug therapy , B7-2 Antigen/biosynthesis , B7-2 Antigen/drug effects , B7-2 Antigen/immunology , Blotting, Western , Cells, Cultured , Coculture Techniques , Cytokines/biosynthesis , Cytokines/immunology , Down-Regulation , Enzyme-Linked Immunosorbent Assay , Female , Fluorescent Antibody Technique , Humans , Immunohistochemistry , Macrophage Activation/immunology , Macrophages/immunology , Macrophages/metabolism , Male , Middle Aged , Reverse Transcriptase Polymerase Chain Reaction , Synovial Membrane/cytology , Synovial Membrane/drug effects , T-Lymphocytes/immunology
17.
J Rheumatol ; 36(6): 1235-9, 2009 Jun.
Article in English | MEDLINE | ID: mdl-19369451

ABSTRACT

OBJECTIVE: We evaluated endothelin (ET)-1 plasma levels and some clinical measures in patients with primary Raynaud's phenomenon (PRP), and in patients with systemic sclerosis (SSc) and secondary RP (SRP), in the latter according to their different nailfold videocapillaroscopy (NVC) patterns of microangiopathy (early, active, and late). METHODS: Ninety-nine patients with SSc, 49 with PRP, and 45 control subjects were studied. NVC was performed in all patients to distinguish the pattern of microvascular damage, and the morphological alterations were scored by a semiquantitative rating scale. ET-1 plasma levels were evaluated in all individuals by ELISA. RESULTS: ET-1 plasma levels were significantly higher (p=0.001) in patients with both PRP and SRP, compared to controls. A significant positive correlation (p=0.03) was found between ET-1 plasma levels and SRP duration, but not between ET-1 plasma levels and PRP duration. Significant correlations were observed in patients with SSc between ET-1 plasma levels and clinical measures (e.g., digital ulcers), as well as the score value of single NVC measures, such as the number of capillaries, "ramified" capillaries, and enlarged capillaries (p<0.05). Finally, the highest ET-1 plasma levels were found in patients with SSc showing the late pattern of microangiopathy when compared to the early pattern (p=0.03) and to controls (p=0.003). CONCLUSION: Highest ET-1 plasma levels were detected in the more advanced stage of the SSc microangiopathy, namely the late NVC pattern, characterized by capillary loss and increased tissue fibrosis; this might support the involvement of ET-1 in the progression of the microvascular/fibrotic SSc damage.


Subject(s)
Endothelin-1/blood , Microscopic Angioscopy/methods , Raynaud Disease/pathology , Scleroderma, Systemic/pathology , Adolescent , Adult , Aged , Capillaries/pathology , Female , Humans , Male , Middle Aged , Raynaud Disease/blood , Raynaud Disease/complications , Scleroderma, Systemic/blood , Scleroderma, Systemic/complications , Skin/blood supply , Skin/pathology , Young Adult
18.
J Autoimmun ; 32(3-4): 254-60, 2009.
Article in English | MEDLINE | ID: mdl-19324522

ABSTRACT

Immune response is greater in females than in males and lymphocytes/monocytes from female subjects (or tested in vitro with estrogens) show higher immune/inflammatory reactivity. In order to test in vitro the interactions between 17beta-estradiol (E2--10(-9) M), testosterone (T--10(-8) M) and the antiproliferative/immune suppressive drug Leflunomide metabolite A77 1726 (LEF-M--30 microM) employed in rheumatoid arthritis (RA), their combined effects were evaluated on inflammatory cytokine (CK) expression/production in cultures of differentiated macrophages (M) (from activated THP-1 monocytes) and primary cultures of RA synovial macrophages (SM). TNFalpha, IL-6 and TGFbeta were detected by immunocytochemistry (ICC), Western blot analysis (WB) and reverse transcriptase-polymerase chain reaction (RT-PCR). The ICC, WB and RT-PCR showed a significant down-regulation induced by LEF-M on CK expression by cultured M when compared to untreated cells (IL-6 p < 0.01, TNFalpha p < 0.001, TGFbeta p < 0.01). At ICC analysis E2 increased CK expression, whereas T decreased the expression, confirmed by WB and RT-PCR (range between p < 0.05 and p < 0.001). LEF-M treatment significantly downregulated the CK expression in E2/T treated M: the effect was more significant in LEF-M plus T-treated cells versus controls (range between p < 0.01 and p < 0.001). Concerning the RA SM, the results were replicated (range between p < 0.05 and p < 0.001). E2 seems to contrast, but T seems to synergize the LEF-M activity. Results might support a stronger therapeutical efficacy, at least for LEF, in male RA patients, as already reported by clinical evidences.


Subject(s)
Anti-Inflammatory Agents, Non-Steroidal/pharmacology , Arthritis, Rheumatoid/drug therapy , Cytokines/biosynthesis , Estradiol/metabolism , Isoxazoles/pharmacology , Testosterone/metabolism , Adult , Aniline Compounds/pharmacology , Anti-Inflammatory Agents, Non-Steroidal/therapeutic use , Arthritis, Rheumatoid/immunology , Cell Line , Crotonates , Estradiol/pharmacology , Female , Humans , Hydroxybutyrates/pharmacology , Interleukin-6/biosynthesis , Isoxazoles/therapeutic use , Leflunomide , Macrophages/drug effects , Macrophages/immunology , Male , Middle Aged , Monocytes/drug effects , Monocytes/immunology , Nitriles , Testosterone/pharmacology , Toluidines , Transforming Growth Factor beta/biosynthesis , Tumor Necrosis Factor-alpha/biosynthesis
20.
Autoimmun Rev ; 8(2): 153-5, 2008 Dec.
Article in English | MEDLINE | ID: mdl-18703175

ABSTRACT

Glucocorticoids (GC) exert many complex quantitative and qualitative immunosuppressive effects that induce cellular immunodeficiency and consequently might increase host susceptibility to various viral, bacterial, fungal, and parasitic infections. In chronic immune/inflammatory conditions cortisol is secreted at inadequate levels and GC therapy today is devoted in substituting this hormone in adequate doses (low) to compensate just for this; therefore, the correct timing of GC administration, such as given during the turning-on phase of TNF secretion (night), can be of major importance. Consequently, the use of the lowest possible GC dose, at the night time and even for the shortest possible time, should decrease dramatically the risk of infections.


Subject(s)
Glucocorticoids/adverse effects , Immunosuppressive Agents/adverse effects , Infections/immunology , Glucocorticoids/administration & dosage , Humans , Immunity/drug effects , Immunosuppressive Agents/administration & dosage , Infections/microbiology , Infections/parasitology
SELECTION OF CITATIONS
SEARCH DETAIL
...